Synthesis and *in vitro* evaluation of piperazinyl-ureido sulfamates as steroid sulfatase inhibitors

Davide Moi,^{a†} Paul A. Foster,^{b, c†} Lucy G. Rimmer,^b Alisha Jaffri,^b Alessandro Deplano,^{a§} Gianfranco Balboni,^a Valentina Onnis,^{a*} and Barry V. L. Potter^{d*}

^aDepartment of Life and Environmental Sciences, Unit of Pharmaceutical, Pharmacological and Nutraceutical Sciences, University of Cagliari, via Ospedale 72, Cagliari I-09124, Italy

^bInstitute of Metabolism and Systems Research, University of Birmingham, 2nd Floor IBR Tower, Birmingham, B15 2TT, UK

^cCentre for Endocrinology, Diabetes and Metabolism, Birmingham Health Partners, Birmingham, B15 2TH, UK

^dMedicinal Chemistry & Drug Discovery, Department of Pharmacology, University of Oxford, Mansfield Road, Oxford, OX1 3QT, UK

*To whom correspondence should be addressed. E-mail: vonnis@unica.it; barry.potter@pharm.ox.ac.uk

†These authors contributed equally to the present paper

§present address: Pharmacelera, Placa Pau Vila, 1, Sector 1, Edificio Palau de Mar, Barcelona 08039, Spain

Highlights

- * Piperazinyl-ureido sulfamates were designed and synthesised.
- * Synthesised compounds were assayed *in vitro* as steroid sulfatase (STS) inhibitors.
- * Synthesised compound inhibited STS with micromolar to low nanomolar potency.
- * Selected STS inhibitors are membrane permeant in a JEG-3 human placenta choriocarcinoma cell line.
- * The sulfamates **19** and **20** had STS IC₅₀ values of 5.1 and 8.8 nM respectively.

Keywords

Piperazines, Ureido compounds, Sulfamates, Pyrimidines, Steroid sulfatase, Enzyme inhibition.

Graphical abstract

Abstract

Two new piperazinyl-ureido single ring aryl sulfamate-based inhibitor series were designed against the emerging oncology drug target steroid sulfatase (STS), for which there are existing potent steroidal and non-steroidal agents in clinical trials. 4-(Piperazinocarbonyl)aminosulfamates (**5-31**) were obtained by reacting 4-hydroxyarylamines with phenylchloroformate, subsequent sulfamoylation of the resulting hydroxyarylcarbmates and coupling of the product with 1-substituted piperazines. Pyrimidinyl-piperazinourea sulfamates (**35-42**) were synthesized by pyrimidine ring closure of 4-Boc-piperazine-1-carboxamidine with 3-(dimethylamino)propenones, deprotection and coupling with the sulfamoylated building block. Target ureidosulfamates **5-31** and **35-42** were evaluated both as STS inhibitors *in vitro* using a lysate of JEG-3 human placenta choriocarcinoma cell line and in a whole cell assay. SAR conclusions were drawn from both series. In the series **35-42** the best inhibitory activity is related to the presence of a benzofuryl on the pyrimidine ring. In the series **5-31** the best inhibitory activity was shown by the ureas bearing 4-chlorophenyl, 3,4-dichlorophenyl groups or aliphatic chains at the piperazino 4-nitrogen displaying IC_{50} in the 33-94 nanomolar concentration range. Final optimization to the low nanomolar level was achieved through substitution of the arylsulfamate ring with halogens. Four halogenated arylsulfamates of high potency were achieved and two of these **19** and **20** had IC_{50} values of 5.1 and 8.8 nM respectively and are attractive for potential *in vivo* evaluation and further development. We demonstrate the optimization of this new series to low nanomolar potency, employing fluorine substitution, providing potent membrane permeant inhibitors with further development potential indicating piperazinyl-ureido aryl sulfamate derivatives as an attractive new class of STS inhibitors.

1. Introduction

Estrogen signalling is a well-established target for breast cancer drug discovery [1] with clinical drugs such as Tamoxifen, acting at the estradiol receptor, and aromatase inhibitors blocking biosynthetic conversion of androgens to estrogens, the main standards of clinical care. More recently, a new drug target steroid sulfatase (STS) has become an emerging new therapeutic modality with its inhibition showing clinical benefit and the first clinical trial data published in 2006 [2]. STS is widely distributed throughout the body and is involved in numerous physiological and pathological conditions [3] including hormone-dependent cancers [4], lysosomal storage disorders, developmental abnormalities, and bacterial pathogenesis [5]. Primarily, STS catalyzes the desulfation of biologically inactive steroid sulfates into their bioactive forms. It can work in an intracrine fashion, playing a crucial role in the *in situ* formation of biologically active steroids such as estradiol or androstenediol in tumor cells in hormone-dependent disease [6].

Numerous STS inhibitors have already been described in the literature and these have mainly focused on the sulfamate ester class of compound, first discovered by some of us [7]. Initial potent STS inhibitors were

steroid-based: estrone and estradiol-based aryl sulfamate esters are known to be time and concentration dependent irreversible active-site directed inhibitors [8]. However, because of their very potent estrogenic activity in rodents they were not deemed suitable for progression as anti-tumor drug candidates, although one of them, estradiol 3-*O*-sulfamate (Figure 1, **E2MATE**), did reach phase II human clinical trials as a prodrug of estradiol in hormone replacement therapy [9,10]. E2MATE is still being pursued as a potential drug against the hormone-dependent disease endometriosis [11-12], that was shown to have an important STS component [13].

Figure 1. Structures of the STS inhibitors E2MATE and Irosustat

While many further steroidal based sulfamate-based inhibitors have been designed [9, 14, 15], because of estrogenicity issues the search for non-estrogenic STS inhibitors was prioritised and many structurally diverse inhibitors with different scaffolds combined with the sulfamate moiety have been reported [1, 9]. Initially, those possessing a coumarin-based template were highly effective [16-18]. Coumarin-7-*O*-sulfamate and derivatives such as COUMATE showed high STS inhibitory activity and no significant estrogenicity [19]. Further development in this area led to the clinical STS inhibitor Irosustat/STX64 (Figure 1) [2, 17]. Such aryl sulfamate derivatives in particular have proved to be the most potent STS inhibitors and have reached clinical trials [9, 10]. The most recent clinical reports relate to two studies, one with Irosustat in combination with an aromatase inhibitor [20] and another demonstrating the first effects of Irosustat in early breast cancer in treatment-naïve patients [21]. Aryl sulfamate-based drugs are thought to work by sulfamoyl group transfer to the active site hydrated formylglycine residue important for catalysis by STS, leading to irreversible inactivation of the enzyme [10].

Further work on STS inhibitor development included synthesizing reversible inhibitors without a sulfamate moiety, although these have not reached clinical evaluation [22, 23]. Other types of irreversible inhibitors that can produce reactive quinone methides upon activation by STS [24] and other alternatives to the sulfamate ester approach [25-27] have been investigated. Dual inhibitors of both STS and aromatase have also been reported, some with dual picomolar potency against both enzymes [28]. Sulfamate analogs of *N*-acylated tyramine containing C–F bonds demonstrate that introduction of a fluorine atom into tyramine-based STS inhibitors remote from the aryl sulfamate moiety can enhance inhibitory activity, albeit in the micromolar range [29]. Recent work by some of us has shown that the introduction of halogens, particularly fluorine into the aryl sulfamate ring can appreciably improve the activity of STS inhibitors by lowering the

pKa of the leaving phenol after transfer of the sulfamoyl moiety, thus increasing the “sulfamoyl-transfer potential” of the inhibitor [9, 10, 30].

Non-steroidal STS inhibitors have often included a sulfamoylated fused AB phenolic ring steroid surrogate motif, although early examples with employing single ring also showed good potency [31, 32] as did that using a single ring of a biphenyl template [33]. Recently, some of us explored further development of non-fused aryl sulfamate esters as potential STS inhibitors. Thus, simple arylamide derivatives **A** possessing especially terminal sulfamate moieties (Figure 2) were synthesized. One compound with $n=2$ had an IC_{50} of 421 nM and was an effective STS inhibitor in whole cells, showing potential for further optimization [34].

Figure 2. Structures of arylamide sulfamates (**A**) and design of the new piperazino ureido sulfamates of this paper.

In the present study, we explored a series of broadly related piperazinyureas bearing the arylsulfamate moiety to further optimize this lead. In an effort to define the critical requirements for activity and understand the molecular determinants of such novel STS inhibitors, our approaches involved making structural modifications in the putative key pharmacophoric portions of the molecule. Our starting approach was focused upon synthesizing a series of sulfamate derivatives bearing on their scaffold a large number of aliphatic/aromatic/heterocyclic moieties (substituting the second nitrogen atom from the piperazine ring) in order to generate chemical diversity and to incorporate a piperazine group to improve physicochemical properties. Starting from the compound **A**, the amide moiety was replaced with an ureido group to allow strong hydrogen bonding which might lead to cooperative effects [35, 36]. Furthermore, the ureido linker was connected to a more rigid heterocyclic system, the N-substituted piperazine ring. Piperazine ring is a well-known heterocyclic structure present in many biologically active molecules. Constraining the polar nitrogen atoms into the piperazine ring can confer more drug-like properties to molecules and enhance favourable interactions with macromolecules [37, 38]. Herein we report the synthesis of a series of these ligands and *in vitro* results of an STS inhibition study using the lysate of JEG-3, a human placenta choriocarcinoma cell line known to have high STS activity. Additionally, membrane permeability was explored using STS inhibition in intact JEG-3 cells.

2. Results and discussion

2.1. Chemistry

The synthesis of the new compounds is reported in Schemes 1 and 2. Hydroxyarylcabamates **3** were obtained with good yields by reacting 4-hydroxyarylamines **1** with phenylchloroformate **2** in the presence of

N,N-diisopropylethylamine (DIPEA). Sulfamoylation of aryl carbamates **3** upon treatment with sulfamoyl chloride [39] in *N,N*-dimethylacetamide (DMA) solution furnished the key intermediates **4**. Coupling of **4** with 1-substituted piperazines in DMSO solution gave the piperazinyl urea derivatives **5-31** (Scheme 1).

Scheme 1. Reagents and conditions: (i) DIPEA, THF, r.t. 24 h; (ii) ClSO₂NH₂, DMA, r.t. 12 h; (iii) Substituted piperazine, DMSO, r.t. 24 h.

A pyrimidinyl-piperazinourea series **35-42** was synthesized by heterocyclization of 4-Boc-piperazine-1-carboxamide (**32**) with 3-(dimethylamino)propenones **33a-h** in boiling 1-propanol, followed by trifluoroacetic acid (TFA)-mediated deprotection in dichloromethane (DCM) solution and then coupling with 4-((phenoxycarbonyl)amino)phenyl sulfamate (**4a**) (Scheme 2).

Scheme 2. Reagents and conditions: (i) 1-propanol, reflux 12 h; (ii) TFA, DCM, r.t. 24 h; (iii) **4a**, DIPEA, DMSO, r.t. 24 h.

2.1. STS inhibition

The *in vitro* STS inhibition of activity of the sulfamates **5-31** and **35-42** was measured in an assay using a JEG-3 cell lysate. The *in vitro* inhibition results are reported as % of residual STS at 10 μ M inhibitor concentration (Tables 1, 2, and 3), and IC₅₀ values were determined in the relevant cases (Figures 4-6). Compounds showing strong STS inhibition were selected for whole cell experiments to assess the ability to cross a lipid bilayer using intact monolayers of JEG-3 cells (Figures 3 and 6).

Table 1. STS inhibitory activity of sulfamates of the hydroxyarylcarbamate series **5-18**.

Compound	R	Residual STS % activity $\pm$ SD ^a
5		18.7 $\pm$ 1.6
6		16.9 $\pm$ 3.3
7		10.4 $\pm$ 1.9
8		14.9 $\pm$ 1.6
9		47.9 $\pm$ 6.3
10		93.5 $\pm$ 6.5
11		37.0 $\pm$ 2.4
12		26.3 $\pm$ 1.9
13		23.0 $\pm$ 3.4
14		5.9 $\pm$ 0.8

15		20.2 ± 0.7
16	<i>n</i> -heptyl	27.7 ± 1.6
17	<i>n</i> -octyl	12.4 ± 2.7
18	<i>n</i> -decyl	3.5 ± 0.7

^aResidual activity after JEG-3 cell lysate treatment with 10μM inhibitor is shown.

Figure 3. Evaluation of sulfamates **5-7** (A), **13** and **16** (B), **8**, **17** and **18** (C) in whole cell JEG-3. All compounds were tested at 10 μM, the reference inhibitor STX64 was used as positive control. All data represents mean ± S.D., n = 3

The following structure activity relationship (SAR) may be noted regarding the inhibition data of compounds **5-18** shown in Table 1 and Figure 3. The benzylpiperazine urea **5** showed good STS residual activity (18.7% ± 1.6) in isolated enzyme assay as well as in intact JEG-3 cells (19.5% ± 1.3). The removal of the methylene linker to give sulfamate **6** did not produce significant changes in inhibitory activity against the isolated enzyme, while the activity on JEG-3 was about a half as compared to compound **5** (32.8% ± 6.2). The introduction of a methyl group into 3-position of aromatic ring (compound **7**) produced an increase in activity against isolated enzyme and cells (23.4% ± 1.1). The shift of the methyl group to the 2-position to give urea **9** highly reduced the activity. On the contrary, the introduction of a second methyl group as in compound **14** produced high activity on the isolated enzyme. The replacement of the 3-methyl group of compound **7** with a 3-methoxy group to give the urea **12** provided reduction of inhibitory activity as well as the shift of the

methoxy into 4-position (urea **11**). The 4-fluorine substituted urea **10** showed poor activity, while the replacement of the fluorine with a 4-chlorine atom afforded the high active urea **8**. The introduction of a second chlorine atom to give compound **13** produced reduction in activity on the isolated enzyme and $3.6\% \pm 2.3$ on JEC-3 cells (Figure 3). The replacement of the benzyl group of compound **5** with a benzofurymethyl (urea **15**) did not afford significant change in inhibitory activity. However, the replacement of the benzyl group with aliphatic chains to give compounds **16-18** produced good inhibitory activity being the potency of the ureas as much strong as the chain carbon atom number is increased. In summary, the best inhibitory activity was showed by the ureas bearing 4-chlorophenyl, 2,3-dimethylphenyl groups or aliphatic chains. The compounds showing the best activity were evaluated for their IC_{50} values in STS inhibition (Table 4). Compounds **13** and **16** showed IC_{50} values of $1.23 \mu M$ and $1.69 \mu M$ respectively. While relatively modest, this was nevertheless encouraging, and further substitutions produced compounds in the nM potency range, ie **17**, **18**, **8** and **14** for which IC_{50} values were determined as 43.7 nM, 33.2 nM, 94.0 nM and 66.0 nM respectively (Figure 4).

Figure 4. IC_{50} of STS inhibition determined for sulfamates **8**, **13**, **16**, **17**, and **18**, using JEG-3 protein. All data represents mean $\pm$ S.D., $n = 3$

It has been reported that introduction of fluorine atoms into of biologically active compounds is a strategy to enhance their activity and to modify their absorption, distribution, metabolism, and excretion. In general, H/F exchange produces a more lipophilic molecule. Moreover, in the case of STS inhibitors possessing the aryl sulfamate pharmacophore generally substitution of the aromatic ring with electron-withdrawing groups including halogenation, even when not directly on the ring, lowers the pK_a of the departing phenolic group

in the irreversible inhibition process and invariably increases overall potency considerably. Thus, we designed a second series of ureas bearing substituted moieties unchanged but introducing fluorine and chlorine atoms on the sulfamoylated aromatic ring (Table 2, 4 and Figure 5).

Table 2. STS inhibitory activity of sulfamates of the hydroxyarylcarbamate series **19-31**.

Compound	X	R	Residual STS % activity $\pm$ SD ^a
19	2-F		7.1 $\pm$ 0.7
20	2-F	<i>n</i> -octyl	11.4 $\pm$ 0.8
21	2-F	<i>n</i> -decyl	15.2 $\pm$ 3.3
22	2-Cl		110 $\pm$ 10.8
23	2-Cl		15.1 $\pm$ 0.2
24	2-Cl	<i>n</i> -octyl	13.9 $\pm$ 1.5
25	2-Cl	<i>n</i> -decyl	25.4 $\pm$ 0.4
26	3-F		107.9 $\pm$ 6.2
27	3-F		108.8 $\pm$ 3.2
28	3-F	<i>n</i> -octyl	29.6 $\pm$ 1.2
29	3-F	<i>n</i> -decyl	7.8 $\pm$ 1.2
30	3-Cl	<i>n</i> -octyl	71.6 $\pm$ 4.8
31	3-Cl	<i>n</i> -decyl	102.1 $\pm$ 3.5

^aResidual activity after JEG-3 cell lysate treatment with 10 μ M inhibitor is shown.

Figure 5. The IC_{50} of the most potent haloarylcarbamate sulfamates (**19**, **20**, **23** and **24**) determined using JEG-3 protein. All data represents mean $\pm$ S.D., $n = 3$

The introduction of a 2-fluorine atom indeed produced an expected improvement in activity as shown by the paired comparison of the activity of compound **8** (IC_{50} 94 nM) with compound **19** (IC_{50} 5.1 nM) activity and compound **17** (IC_{50} 43.7 nM) with compound **20** (IC_{50} 8.8 nM). On the contrary, compound **18** shows high activity as compared with the fluorine analog **21**. The replacement of the 2-fluorine with a 2-chlorine produced variable results. Compound **22** ($110\% \pm 10.8$) is about ten times less active as compared to the unsubstituted analog **8** ($14.9\% \pm 1.6$). The comparison of urea **14** (IC_{50} 66 nM) and urea **23** (IC_{50} 17 nM) activity indicated a positive effect of the chlorine atom on the inhibitory activity. The comparison of compound **20** and compound **24** (IC_{50} 18.9 nM) indicated a slight reduction in inhibitory activity, while the activity drop in compound **25** ($25.4\% \pm 0.4$) confirming the trend showed by the comparison of compounds **18** and **21**. The shift on fluorine or chlorine atoms into 3-position led reduction in activity as compared with the unsubstituted analogs and the corresponding 2-fluorine or 2-chlorine isomers except for compound **29** ($7.8\% \pm 1.2$) that showed better than the isomer **21** ($15.2\% \pm 3.3$). Thus, final optimisation yielded a set of low nM potent halogenated inhibitors, two of which **19** and **20** with IC_{50} values of 5.1 and 8.8 nM respectively seem ideally suited for further development.

The third series of ureidosulfamates was designed by introduction on the piperazine nitrogen of 6-arylpyrimidine moieties and led to ureas **35-41** showing STS residual activity ranging from 7.9 to 60.7% (Table 3).

Table 3. STS inhibitory activity of sulfamates **35-42**.

Compound	Ar	Residual STS % activity $\pm$ SD ^a
35		65.9 $\pm$ 5.4
36		7.9 $\pm$ 1.3
37		26.7 $\pm$ 8.5
38		39.4 $\pm$ 9.9
39		44.3 $\pm$ 1.0
40		60.7 $\pm$ 9.4
41		19.0 $\pm$ 3.1
42		4.7 $\pm$ 0.7

^aResidual activity after JEG-3 cell lysate treatment with 10 μ M inhibitor is shown.

Figure 6. A) Evaluation of the STS inhibitory activity of sulfamate compounds **36** and **42** in whole cell JEG-3 tested at 10 μ M, the reference inhibitor STX64 was used as positive control. B) STS inhibition IC_{50} value of compound **42** determined using JEG-3 protein. All data represents mean $\pm$ S.D., $n = 3$.

The best activity in the case of a single aryl substitution was shown by the 4-methoxyphenyl urea **36** ($7.9\% \pm 1.3$, HEC-3 $13.7\% \pm 2.6$, Figure 6) both on isolated enzyme and whole cells. The introduction of further methoxy groups led to a slight reduction in activity as in compound **41** ($19.0\% \pm 3.1$) or a deep reduction of activity as in compound **40** ($60.7\% \pm 9.4$). The removal of substituents as in compound **35** or the introduction of substituents into the 3-position to afford ureas **37-39** produced reduction of activity. The replacement of the aryl ring on the pyrimidine with a benzofuran ring to give compound **42** ($4.7\% \pm 0.7$) produced a high increase in activity as compared to compound **36** especially in JEG-3 cells ($4.1\% \pm 0.9$). With this encouraging potency sulfamate **42** was thus chosen for IC_{50} evaluation and it exhibited a value of 139 nM (Figure 6) which already surpassed that of compound class **A** [34]. IC_{50} values for the most optimized compounds are shown collected in Table 4.

Table 4. Summary IC_{50} values for STS inhibition

Compound	X	R	STS inhibition IC_{50}
8	H		94.0 nM
13	H		1.23 μ M
14	H		66.0 nM
16	H	<i>n</i> -heptyl	1.69 μ M

17	H	<i>n</i> -octyl	43.7 nM
18	H	<i>n</i> -decyl	33.2 nM
19	2-F		5.1 nM
20	2-F	<i>n</i> -octyl	8.8 nM
23	2-Cl		17.0 nM
24	2-Cl	<i>n</i> -octyl	18.9 nM
42	H		139 nM

3. Conclusions

Following on from an initial arylamide series of aryl sulfamate-based inhibitors of steroid sulfatase of moderate potency two new series of piperazinyl-ureido aryl sulfamate-based STS inhibitors were designed and synthesized. Hydroxyarylcarbamates **3** were obtained by reacting 4-hydroxyarylamines with phenylchloroformate and subsequent sulfamoylation and coupling of the product with 1-substituted piperazines to give piperazinyl urea derivatives **5-31**. A pyrimidinyl-piperazinourea series **35-42** was also synthesized by heterocyclization of 4-Boc-piperazine-1-carboxamidine with 3-(dimethylamino)propenones, followed by deprotection and subsequent coupling with the sulfamoylated building block. The ability of the target compounds both to inhibit STS *in vitro* using a JEG-3 human placenta choriocarcinoma cell line lysate and to inhibit STS in a whole cell evaluation of membrane permeability was explored using STS inhibition in intact JEG-3 cells. SAR conclusions were drawn from both series and a progression from the micromolar through to nanomolar inhibition level was achieved by varying substitution patterns. Selected compounds were chosen for final optimization through arylsulfamate ring substitution with halogens. Ultimately, four compounds of low nanomolar potency were achieved and two of these **19** and **20** with IC₅₀ values of 5.1 and 8.8 nM respectively are attractive for further development and potential *in vivo* evaluation. Thus, the replacement of arylamide moiety with a piperazinyl-ureido group high increases STS inhibitory activity and piperazinyl-ureido aryl sulfamate derivatives represent an attractive new class of STS inhibitors.

4. Experimental section

4.1. General methods

All commercially available solvents and reagents were used without further purification. NMR spectra were recorded on an Inova 500 spectrometer (Varian, Palo Alto, CA, USA). The chemical shifts are reported in part per million downfield from tetramethylsilane (TMS) and the spectra were recorded in hexadeuteriodimethylsulphoxide (DMSO-d₆). Infrared spectra were recorded on a Vector 22 spectrometer

(Bruker, Bremen, Germany) in Nujol mulls. The main bands are given in cm^{-1} . Positive-ion electrospray ionization (ESI) mass spectra were recorded on a double-focusing MAT 95 instrument (Finnigan, Waltham, MA, USA) with BE geometry. Melting points (mp) were determined with a SMP1 Melting Point apparatus (Stuart Scientific, Stone, UK) and are uncorrected. All products reported showed spectral data in agreement with the assigned structures. The purity of the tested compounds was determined by combustion elemental analyses conducted by the Microanalytical Laboratory of the Chemistry Department of the University of Ferrara with a MT-5 CHN recorder elemental analyser (Yanagimoto, Kyoto, Japan) and the values found were within 0.4% of theoretical values. 4-(Phenoxycarbonyl)aminophenylsulfamate **4a** [36], 4-Boc-piperazine-1-carboxamidine **32** [37] and sulfamates **5-8**, **10-12**, **14**, **35-39**, **41**, **42** [38] were synthesized as previously described.

4.2. Chemistry

4.2.1. 1-(Benzofuran-2-ylmethyl)piperazine

To a solution of *N*-Boc-piperazine (0.13 g, 0.7 mmol) in CH_2Cl_2 (10 mL) benzofuran-2-carboxaldehyde (0.13 mL, 1.1 mmol), sodium NaHCO_3 (0.07 g, 0.84 mmol) and sodium triacetoxyborohydride (0.21 g, 1 mmol) were added; the mixture was then stirred at r.t. for 48h. Then the reaction mixture was basified to pH 10 with a solution of NaOH 0.1 N and extracted with CH_2Cl_2 (3 x 20 mL). The organic phases were collected, dried over sodium Na_2SO_4 , filtrated and the solvent removed to obtain the desired compound. The obtained residue was dissolved in dichloromethane (10 mL) without further purification, added trifluoroacetic acid (5 mL) and stirred at r.t. for 24h. Then the solvent was removed under vacuum and to the residue obtained diethyl ether (20 mL) was added, leading to formation of a solid that was filtered to give the title compound. Yield 74%. M.p. 123-124 °C. ^1H NMR (DMSO-d_6) δ 2.76 (s, 4H, CH_2), 3.14 (s, 4H, CH_2), 3.87 (s, 2H, CH_2), 6.88 (s, 1H, Ar), 7.23 (d, $J = 7.5$ Hz, 1H, Ar), 7.29 (d, $J = 8.0$ Hz, 1H, Ar), 7.55 (d, $J = 7.5$ Hz, 1H, Ar), 7.62 (d, $J = 8.0$ Hz, 1H, Ar), 8.66 (s, 1H, NH). IR (Nujol) 1667 cm^{-1} . m/z 217 ($\text{M} + \text{H}^+$). Anal. Calcd. for $\text{C}_{13}\text{H}_{16}\text{N}_2\text{O}$ (216.28) C, 72.19; H, 7.46; N, 12.95. Found % C, 72.27; H, 7.48; N, 12.91.

4.2.2. General procedure for the preparation of phenyl(4-hydroxyaryl)-carbamates (**3b-e**)

To an ice-cooled stirred solution of the appropriate 4-hydroxyarylamine (5 mmol) and DIPEA (0.69 mL, 4 mmol) in anhydrous THF (10 mL) phenylchloroformate (0.5 mL, 4 mmol) was added dropwise. The reaction mixture was stirred at room temperature for 24 hours, then water (100 mL) was added; the mixture was stirred for additional 2 h, the formed solid filtered off, and vacuum dried to give carbamates.

4.2.2.1. Phenyl *N*-(3-fluoro-4-hydroxyphenyl)carbamate (**3b**)

Following the general procedure, the title compound was prepared starting from 2-fluoro-4-hydroxyphenyl amine. Yield 88%. M.p. 129-130 °C. ^1H NMR (DMSO-d_6) δ 6.91 (m, 1H, Ar), 7.07 (m, 1H, Ar), 7.21 (m, 3H, Ar), 7.35 (m, 1H, Ar), 7.43 (m, 2H, Ar), 9.54 (s, 1H, NH), 10.09 (s, 1H, OH). IR (Nujol) $3321, 1718, 1615\text{ cm}^{-1}$. m/z 248 ($\text{M} + \text{H}^+$). Anal. Calcd. for $\text{C}_{13}\text{H}_{10}\text{FNO}_3$ (247.22) C, 63.16; H, 4.08; N, 5.67. Found C, 63.23; H, 4.06; N, 5.70.

4.2.2.2. Phenyl N-(3-chloro-4-hydroxyphenyl)carbamate (**3c**)

Following the general procedure, the title compound was prepared starting from 3-chloro-4-hydroxyphenyl amine. Yield 79%. M.p. 132-133 °C. ¹H NMR (DMSO-d₆) δ 6.93 (m, 1H, Ar), 7.07 (m, 1H, Ar), 7.22 (m, 2H, Ar), 7.36 (m, 1H, Ar), 7.43 (m, 2H, Ar), 7.52 (m, 1H, Ar), 9.89 (s, 1H, NH), 10.07 (s, 1H, OH). IR (Nujol) 3385, 1776, 1716, 1597 cm⁻¹. m/z 264 (M + H)⁺. Anal. Calcd. for C₁₃H₁₀ClNO₃ (263.68) C, 59.22; H, 3.82; N, 5.31. Found C, 59.16; H, 3.84; N, 5.28.

4.2.2.3. Phenyl N-(2-fluoro-4-hydroxyphenyl)carbamate (**3d**)

Following the general procedure, the title compound was prepared starting from 3-fluoro-4-hydroxyphenyl amine. Yield 90%. M.p. 126-127 °C. ¹H NMR (DMSO-d₆) δ 6.62 (m, 2H, Ar), 7.19 (m, 2H, Ar), 7.26 (m, 2H, Ar), 7.41 (m, 2H, Ar), 9.52 (s, 1H, NH), 9.82 (s, 1H, OH). IR (Nujol) 3425, 3403, 1730, 1639, 1610 cm⁻¹. m/z 248 (M + H)⁺. Anal. Calcd. for C₁₃H₁₀FNO₃ (247.22) C, 63.16; H, 4.08; N, 5.67. Found C, 63.09; H, 4.10; N, 5.64.

4.2.2.4. Phenyl N-(2-chloro-4-hydroxyphenyl)carbamate (**3e**)

Following the general procedure, the title compound was prepared starting from 2-chloro-4-hydroxyphenyl amine. Yield 90%. M.p. 128-129 °C. ¹H NMR (DMSO-d₆) δ 6.76 (m, 1H, Ar), 6.90-7.41 (m, 7H, Ar), 9.30 (s, 1H, NH), 9.89 (s, 1H, OH). IR (Nujol) 3379, 1736, 1698, 1615 cm⁻¹. m/z 264 (M + H)⁺. Anal. Calcd. for C₁₃H₁₀ClNO₃ (263.68) C, 59.22; H, 3.82; N, 5.31. Found C, 59.28; H, 3.84; N, 5.35.

4.2.3. General procedure for the preparation of 4-(phenoxycarbonyl)aminoarylsulfamate (**4b-e**)

To a stirred solution of phenyl(4-hydroxylaryl)-carbamate (5 mmol) in anhydrous DMA (10 mL, 114 mmol), freshly prepared sulfamoyl chloride (0.81 g, 7 mmol) in DMA (5 mL, mmol) was added dropwise in 30 min. The mixture was stirred at room temperature overnight, then water (20 mL) was added. The mixture was stirred for an additional 2h, then the white solid formed was filtered off and dried to give sulfamates in good purity to be used in the next step without further purification.

4.2.3.1. 3-Chloro-4-((phenoxycarbonyl)amino)phenyl sulfamate (**4b**)

Following the general procedure, the title compound was prepared starting from phenyl N-(3-chloro-4-hydroxyphenyl)carbamate. Yield 40%. M.p. 109-110°C. ¹H NMR (DMSO-d₆) δ 6.75 (m, 1H, Ar), 6.89 (m, 1H, Ar), 7.23-7.41 (m, 6H, Ar), 8.15 (s, 2H, NH₂), 9.89 (s, 1H, NH). IR (Nujol) 3319, 3224, 1738, 1588 cm⁻¹. m/z 343 (M + H)⁺. Anal. Calcd. for C₁₃H₁₁ClN₂O₅S (342.75) C, 45.55; H, 3.23; N, 8.17. Found C, 45.61; H, 3.25; N, 8.20.

4.2.3.2. 2-Chloro-4-((phenoxycarbonyl)amino)phenyl sulfamate (**4c**)

Following the general procedure, the title compound was prepared starting from phenyl N-(2-chloro-4-hydroxyphenyl)carbamate. Yield 36%. M.p. 120-121°C. ¹H NMR (DMSO-d₆) δ 7.23 (m, 3H, Ar), 7.43 (m, 4H, Ar), 7.71 (s, 1H, Ar), 8.17 (s, 2H, NH₂), 10.48 (s, 1H, NH). IR (Nujol) 3302, 3216, 1752, 1591 cm⁻¹. m/z 343 (M + H)⁺. Anal. Calcd. for C₁₃H₁₁ClN₂O₅S (342.75) C, 45.55; H, 3.23; N, 8.17. Found C, 45.49; H 3.24; N, 8.14.

4.2.3.2. 3-Fluoro-4-((phenoxycarbonyl)amino)phenyl sulfamate (**4d**)

Following the general procedure, the title compound was prepared starting from phenyl (3-fluoro-4-hydroxyphenyl)carbamate. Yield 62%. M.p. 117-118°C. ¹H NMR (DMSO-d₆) δ 6.44 (m, 1H, Ar), 6.76 (m, 1H,

Ar), 7.31-7.36 (m, 6H, Ar), 8.20 (s, 2H, NH₂), 9.78 (s, 1H, NH). IR (Nujol) 3315, 3222, 1743, 1579 cm⁻¹. m/z 327 (M + H)⁺. Anal. Calcd. for C₁₃H₁₁FN₂O₅S (326.30) C, 47.85; H, 3.40; N, 8.59. Found C, 47.92; H, 3.38; N 8.55.

4.2.3.3. 2-Fluoro-4-((phenoxycarbonyl)amino)phenyl sulfamate (**4e**)

Following the general procedure, the title compound was prepared starting from phenyl (2-fluoro-4-hydroxyphenyl)carbamate. Yield 56%. M.p. 112-113°C. ¹H NMR (DMSO-d₆) δ 7.27 (m, 4H, Ar), 7.42 (m, 3H, Ar), 7.68 (d, *J* = 8.5 Hz, 1H, Ar), 8.13 (s, 2H, NH₂), 9.81 (s, 1H, NH). IR (Nujol) 3322, 3238, 1744, 1587 cm⁻¹. m/z 327 (M + H)⁺. Anal. Calcd. for C₁₃H₁₁FN₂O₅S (326.30) C, 47.85; H, 3.40; N, 8.59. Found C, 47.79; H, 3.39; N, 8.63.

4.2.4. General procedure for the synthesis of 4-(piperazinocarbonyl)aminosulfamates (**5-31**)

A mixture of 4-(phenoxycarbonyl)aminoarylsulfamate (1 mmol) and substituted 1-substituted piperazine (1 mmol) and DIPEA (0.5 mmol), in anhydrous DMSO (3 mL) was stirred at room temperature for 24 h. Then, water (10 mL) was added and the mixture was stirred at room temperature until a solid is formed. The solid formed was filtered off, washed with water and air dried to give the title ureas.

4.2.4.1. 4-(4-(o-Tolyl)piperazine-1-carboxamido)phenyl sulfamate (**9**)

Following the general procedure, the title compound was prepared starting from o-tolylpiperazine. Yield 72%. M.p. 170-171°C. ¹H NMR (DMSO-d₆) δ 2.29 (s, 3H, CH₃), 2.85 (s, 4H, CH₂), 3.60 (s, 4H, CH₂), 6.98 (d, *J* = 7.0 Hz, 1H, Ar), 7.04 (d, *J* = 8.5 Hz, 1H, Ar), 7.15 (d, *J* = 8.0 Hz, 2H, Ar), 7.18 (d, *J* = 7.0 Hz, 2H, Ar), 7.52 (d, *J* = 8.0 Hz, 2H, Ar), 7.86 (s, 2H, NH₂), 8.70 (s, 1H, NH). ¹³C NMR (DMSO-d₆) δ 17.8, 53.4 (2C), 55.8 (2C), 117.8, 120.8 (2C), 125.2 (2C), 126.6, 127.1, 130.2, 133.6, 139.8, 146.2, 152.3, 157.9. IR (Nujol) 3329, 1647, 1535 cm⁻¹. m/z 391 (M + H)⁺. Anal. Calcd. for C₁₈H₂₂N₄O₄S (390.46) C, 55.37; H, 5.68 N, 14.35. Found C, 55.30; H, 5.66; N, 14.37.

4.2.4.2. 4-(4-(3,4-Dichlorophenyl)piperazine-1-carboxamido)phenyl sulfamate (**13**)

Following the general procedure, the title compound was prepared starting from 3,4-dichlorophenylpiperazine. Yield 98%. M.p. 144-145°C. ¹H NMR (DMSO-d₆) δ 3.23 (m, 4H, CH₂), 3.58 (m, 4H, CH₂), 6.97 (s, 1H, Ar), 7.14 (d, *J* = 8.5 Hz, 2H, Ar), 7.20 (m, 2H, Ar), 7.52 (d, *J* = 8.5 Hz, 2H, Ar), 7.87 (s, 2H, NH₂), 8.72 (s, 1H, NH). ¹³C NMR (DMSO-d₆) δ 52.3 (2C), 53.2 (2C), 111.2, 114.2, 122.4, 122.9, 123.6 (2C), 127.5, 133.0 (2C), 144.2, 144.8 (2C), 157.4. IR (Nujol) 3341, 1649 cm⁻¹. m/z 446 (M + H)⁺. Anal. Calcd. for C₁₇H₁₈Cl₂N₄O₄S (445.32) C, 45.85; H, 4.07; N, 12.58. Found C, 45.92; H, 4.05; N, 12.62.

4.2.4.3. 4-(4-(Benzofuran-2-ylmethyl)piperazine-1-carboxamido)phenyl sulfamate (**15**)

Following the general procedure, the title compound was prepared starting from 1-(benzofuran-2-ylmethyl)piperazine. Yield 40%. M.p. 140-141°C. ¹H NMR (DMSO-d₆) δ 2.54 (s, 2H, CH₂), 3.30 (m, 4H, CH₂), 3.51 (m, 4H, CH₂), 6.81 (s, 1H, Ar), 7.13 (d, *J* = 9.0 Hz, 1H, Ar), 7.16 (d, *J* = 9.0 Hz, 1H, Ar), 7.26 (d, *J* = 9.5 Hz, 1H, Ar), 7.43 (d, *J* = 7.0 Hz, 1H, Ar), 7.46 (d, *J* = 7.0 Hz, 1H, Ar), 7.49 (d, *J* = 9.5 Hz, 1H, Ar), 7.47 (m, 2H, Ar), 7.88 (s, 2H, NH₂), 8.61 (s, 1H, NH). ¹³C NMR (DMSO-d₆) δ 50.1 (2C), 52.2 (2C), 58.3, 103.0, 111.2, 120.9 (2C),

121.6, 123.4 (2C), 123.9, 125.2, 127.1, 131.8, 146.3, 155.1, 155.2, 157.4. IR (Nujol) 3386, 1645 cm^{-1} . m/z 431 ($M + H$)⁺. Anal. Calcd. for $\text{C}_{20}\text{H}_{22}\text{N}_4\text{O}_5\text{S}$ (430.13) C, 55.80; H, 5.15; N, 13.02. Found C, 55.73; H, 5.13; N, 12.98.

4.2.4.4. 4-(4-Heptylpiperazine-1-carboxamido)phenyl sulfamate (**16**)

Following the general procedure, the title compound was prepared starting from *n*-heptylpiperazine. Yield 42%. M.p. 114-115°C. ^1H NMR (DMSO- d_6) δ 0.87 (m, 3H, CH_3), 1.28 (m, 12H, CH_2), 1.48 (m, 2H, CH_2), 3.29 (m, 4H, CH_2), 3.48 (m, 2H, CH_2), 7.14 (s, 2H, Ar), 7.48 (s, 2H, Ar), 7.86 (s, 2H, NH_2), 8.63 (s, 1H, NH). ^{13}C NMR (DMSO- d_6) δ 14.4, 23.2, 26.8, 28.4, 29.6, 32.2, 51.8 (2C), 56.8 (2C), 57.3, 121.1 (2C), 123.6 (2C), 132.5, 148.1, 156.2. IR (Nujol) 3348, 1642, 1538 cm^{-1} . m/z 399 ($M + H$)⁺. Anal. Calcd. for $\text{C}_{18}\text{H}_{30}\text{N}_4\text{O}_4\text{S}$ (398.52) C, 54.25; H, 7.59; N, 14.06. Found C, 54.31; H, 7.57; N, 14.09.

4.2.4.5. 4-(4-Octylpiperazine-1-carboxamido)phenyl sulfamate (**17**)

Following the general procedure, the title compound was prepared starting from *n*-octylpiperazine. Yield 38%. M.p. 154-155°C. ^1H NMR (DMSO- d_6) 0.87 (m, 3H, CH_3), 1.27 (m, 14H, CH_2), 2.36 (s, 4H, CH_2), 3.43 (s, 4H, CH_2), 7.14 (d, $J = 7.0$ Hz, 2H, Ar), 7.49 (d, $J = 7.5$ Hz, 2H, Ar), 7.86 (s, 2H, NH_2), 8.59 (s, 1H, NH). ^{13}C NMR (DMSO- d_6) δ 17.1, 25.2, 30.1, 31.8, 32.0, 34.4 (2C), 42.3 (2C), 55.8 (2C), 60.9, 123.5 (2C), 125.2 (2C), 142.1, 147.6, 158.0. IR (Nujol) 3373, 1642 cm^{-1} . m/z 413 ($M + H$)⁺. Anal. Calcd. for $\text{C}_{19}\text{H}_{32}\text{N}_4\text{O}_4\text{S}$ (412.55) C, 55.32; H, 7.82; N, 13.58. Found C, 55.27; H, 7.98; N, 13.62.

4.2.4.6. 4-(4-Decylpiperazine-1-carboxamido)phenyl sulfamate (**18**)

Following the general procedure, the title compound was prepared starting from *n*-decylpiperazine. Yield 51%. M.p. 159-160°C. ^1H NMR (DMSO- d_6) 0.86 (m, 3H, CH_3), 1.26 (m, 18H, CH_2), 2.38 (s, 4H, CH_2), 3.44 (s, 4H, CH_2), 7.13 (d, $J = 9.0$ Hz, 2H, Ar), 7.50 (d, $J = 9.0$ Hz, 2H, Ar), 7.86 (s, 2H, NH_2), 8.60 (s, 1H, NH). ^{13}C NMR (DMSO- d_6) δ 17.1, 25.3, 31.8 (2C), 32.1 (2C), 32.2, 34.5 (2C), 42.5 (2C), 46.7 (2C), 60.9, 123.5 (2C), 125.2 (2C), 142.1, 147.6, 157.9. IR (Nujol) 3388, 1642 cm^{-1} . m/z 441 ($M + H$)⁺. Anal. Calcd. for $\text{C}_{21}\text{H}_{36}\text{N}_4\text{O}_4\text{S}$ (440.60) C, 57.25; H, 8.24; N, 12.72. Found C, 55.19; H, 8.21; N, 12.76.

4.2.4.7. 4-(4-(4-Chlorophenyl)piperazine-1-carboxamido)-2-fluorophenyl sulfamate (**19**)

Following the general procedure, the title compound was prepared starting from 4-(chlorophenyl)piperazine. Yield 90%. M.p. 102-103°C. ^1H NMR (DMSO- d_6) δ 3.17 (s, 4H, CH_2), 3.60 (s, 4H, CH_2), 6.84 (m, 1H, Ar), 7.00 (d, $J = 8.0$ Hz, 2H, Ar), 7.26 (d, $J = 8.0$ Hz, 2H, Ar), 7.29 (m, 1H, Ar), 7.41 (m, 1H, Ar), 8.09 (s, 2H, NH_2), 8.99 (s, 1H, NH). ^{13}C NMR (DMSO- d_6) δ 42.6 (2C), 51.2 (2C), 111.6 (d, $^2J_{\text{CF}} = 19.1$ Hz), 117.8 (d, $^3J_{\text{CF}} = 8.3$ Hz), 119.1 (d, $^4J_{\text{CF}} = 3.5$ Hz), 120.3 (2C), 125.8, 131.8 (2C), 134.4 (d, $^2J_{\text{CF}} = 13.4$ Hz), 135.6 (d, $^3J_{\text{CF}} = 9.5$ Hz), 142.7, 157.9 (d, $^1J_{\text{CF}} = 242.1$ Hz), 158.2. IR (Nujol) 3325, 1645, 1605 cm^{-1} . m/z 429 ($M + H$)⁺. Anal. Calcd. for $\text{C}_{17}\text{H}_{18}\text{ClFN}_4\text{O}_4\text{S}$ (428.87) C, 47.61; H, 4.23; N, 13.06. Found C, 47.66; H, 4.21; N, 13.10.

4.2.4.8. 2-Fluoro-4-(4-octylpiperazine-1-carboxamido)phenyl sulfamate (**20**)

Following the general procedure, the title compound was prepared starting from 4-octylpiperazine. Yield 15%. M.p. 86-87°C. ^1H NMR (DMSO- d_6) δ 0.87 (t, $J = 6.5$ Hz, 3H, CH_3), 1.27 (m, 14H, CH_2), 2.38 (s, 4H, CH_2), 3.43 (s, 4H, CH_2), 6.81 (m, 1H, Ar), 7.00 (m, 1H, Ar), 7.32 (m, 1H, Ar), 7.41 (s, 2H, NH_2), 8.40 (s, 1H, NH). ^{13}C

NMR (DMSO- d_6) δ 17.0, 25.2, 28.9, 30.0, 31.8, 34.4 (2C), 46.4 (2C), 55.6 (2C), 60.7, 111.6 (d, $^2J_{CF}$ = 22.9 Hz), 119.0 (d, $^3J_{CF}$ = 6.1 Hz), 120.2 (d, $^4J_{CF}$ = 3.9 Hz), 135.6 (d, $^3J_{CF}$ = 8.6 Hz), 142.5 (d, $^2J_{CF}$ = 12.4 Hz), 154.3 (d, $^1J_{CF}$ = 229.8 Hz), 158.1. IR (Nujol) 3323, 1643, 1605 cm^{-1} . m/z 431 ($M + H$) $^+$. Anal. Calcd. for $C_{19}H_{31}FN_4O_4S$ (430.54) C, 53.00; H, 7.26; N, 13.01. Found C, 53.05; H, 7.24; N, 12.97.

4.2.4.9. 4-(4-Decylpiperazine-1-carboxamido)-2-fluorophenyl sulfamate (**21**)

Following the general procedure, the title compound was prepared starting from 4-decylpiperazine. Yield 22%. M.p. 48-49°C. 1H NMR (DMSO- d_6) δ 0.91 (t, J = 7.0 Hz, 3H, CH_3), 1.31 (m, 18H, CH_2), 2.39 (s, 4H, CH_2), 3.39 (s, 4H, CH_2), 6.86 (m, 1H, Ar), 7.11 (m, 1H, Ar), 7.27 (m, 1H, Ar), 7.43 (s, 2H, NH_2), 8.40 (s, 1H, NH). ^{13}C NMR (DMSO- d_6) δ 17.0, 22.7, 25.22, 27.5, 28.2, 30.4, 32.2, 34.7 (2C), 47.1 (2C), 57.3 (2C), 62.2, 113.4 (d, $^2J_{CF}$ = 23.7 Hz), 118.4 (d, $^3J_{CF}$ = 5.4 Hz), 120.9 (d, $^4J_{CF}$ = 4.4 Hz), 133.8 (d, $^3J_{CF}$ = 9.5 Hz), 143.2 (d, $^2J_{CF}$ = 16.2 Hz), 155.4 (d, $^1J_{CF}$ = 232.0 Hz), 156.1. IR (Nujol) 3366, 1644, 1519 cm^{-1} . m/z 459 ($M + H$) $^+$. Anal. Calcd. for $C_{21}H_{35}FN_4O_4S$ (458.59) C, 55.00; H, 7.69; N, 12.22. Found C, 54.93; H, 7.71; N, 12.26.

4.2.4.10. 2-Chloro-4-(4-(4-chlorophenyl)piperazine-1-carboxamido)phenyl sulfamate (**22**)

Following the general procedure, the title compound was prepared starting from 4-chlorophenylpiperazine. Yield 82%. M.p. 84-85°C. 1H NMR (DMSO- d_6) δ 3.16 (s, 4H, CH_2), 3.57 (s, 4H, CH_2), 6.86 (d, J = 8.0 Hz, 2H, Ar), 7.19 (m, 3H, Ar), 7.25 (m, 2H, Ar), 7.51 (s, 2H, NH_2), 8.47 (s, 1H, NH). ^{13}C NMR (DMSO- d_6) δ 52.4 (2C), 54.2 (2C), 116.2 (2C), 117.2, 120.9, 123.0, 124.7, 128.8, 130.2 (2C), 133.5, 148.0, 152.6, 158.0 IR (Nujol) 3279, 1638, 1594 cm^{-1} . m/z 446 ($M + H$) $^+$. Anal. Calcd. for $C_{17}H_{18}Cl_2N_4O_4S$ (445.32) C, 45.85; H, 4.07; N, 12.58. Found C, 45.89; H, 4.09; N 12.61.

4.2.4.11. 2-Chloro-4-(4-(2,3-dimethylphenyl)piperazine-1-carboxamido)phenyl sulfamate (**23**)

Following the general procedure, the title compound was prepared starting from 2,3-dimethylphenylpiperazine. Yield 60%. M.p. 89-90°C. 1H NMR (DMSO- d_6) δ 2.17 (s, 3H, CH_3), 2.20 (s, 3H, CH_3), 2.80 (s, 4H, CH_2), 3.58 (s, 4H, CH_2), 6.88 (m, 2H, Ar), 7.06 (m, 2H, Ar), 7.21 (m, 2H, Ar), 7.52 (s, 2H, NH_2), 8.44 (s, 1H, NH). ^{13}C NMR (DMSO- d_6) δ 16.8, 23.4, 47.4, (2C), 55.0 (2C), 119.8, 123.6 (2C), 125.3 (2C), 128.0, 128.9, 130.7, 140.5, 142.1, 147.7, 154.2, 158.2. IR (Nujol) 3321, 1638, 1592 cm^{-1} . m/z 439 ($M + H$) $^+$. Anal. Calcd. for $C_{19}H_{23}ClN_4O_4S$ (438.93) C, 51.99; H, 5.28; N, 12.76. Found C, 52.05; H, 5.26; N, 12.79.

4.2.4.12. 2-Chloro-4-(4-octylpiperazine-1-carboxamido)phenyl sulfamate (**24**)

Following the general procedure, the title compound was prepared starting from *n*-octylpiperazine. Yield 18%. M.p. 108-110°C. 1H NMR (DMSO- d_6) δ 0.88 (m, 3H, CH_3), 1.29 (m, 14H, CH_2), 2.34 (s, 4H, CH_2), 3.46 (s, 4H, CH_2), 7.17 (d, J = 7 Hz, 1H, Ar), 7.44 (s, 1H, Ar), 7.47 (d, J = 7.5 Hz, 1H, Ar), 7.75 (s, 2H, NH_2), 8.44 (s, 1H, NH). ^{13}C NMR (DMSO- d_6) δ 15.0, 22.7, 26.2, 28.5, 29.0 (2C), 32.7, 53.1 (2C), 58.3 (2C), 61.8, 119.4, 122.2, 123.6, 125.8, 130.7, 154.2, 155.5. IR (Nujol) 3346, 1641, 1595 cm^{-1} . m/z 447 ($M + H$) $^+$. Anal. Calcd. for $C_{19}H_{31}ClN_4O_4S$ (446.99) C, 51.05; H, 6.99; N, 12.53. Found C, 51.12; H, 7.02; N, 12.57.

4.2.4.13. 2-Chloro-4-(4-decylpiperazine-1-carboxamido)phenyl sulfamate (25)

Following the general procedure, the title compound was prepared starting from *n*-decylpiperazine. Yield 70%. M.p. 92-93°C. ¹H NMR (DMSO-*d*₆) δ 0.87 (m, 3H, CH₃), 1.27 (m, 18H, CH₂), 2.36 (s, 4H, CH₂), 3.46 (s, 4H, CH₂), 7.11 (d, *J* = 9.0 Hz, 1H, Ar), 7.46 (d, *J* = 9.0 Hz, 1H, Ar), 7.53 (m, 1H, Ar), 7.61 (s, 2H, NH₂), 9.36 (s, 1H, NH). ¹³C NMR (DMSO-*d*₆) δ 16.8, 25.2, 31.7 (2C), 31.9 (2C), 32.0, 33.1 (2C), 53.1 (2C), 57.6 (2C), 60.2, 119.2, 120.8, 122.4, 124.8, 131.3, 155.0, 157.4. IR (Nujol) 3348, 1633, 1596 cm⁻¹. *m/z* 475 (M + H)⁺. Anal. Calcd. for C₂₁H₃₅ClN₄O₄S (474.04) C, 53.09; H, 7.43; N 11.79. Found C, 53.16; H, 7.45; N, 11.76.

4.2.4.14. 4-(4-(4-Chlorophenyl)piperazine-1-carboxamido)-3-fluorophenyl sulfamate (26)

Following the general procedure, the title compound was prepared starting from 4-chlorophenylpiperazine. Yield 20%. M.p. 94-95°C. ¹H NMR (DMSO-*d*₆) δ 3.16 (s, 4H, CH₂), 3.55 (s, 4H, CH₂), 6.55 (m, 1H, Ar), 6.91 (m, 1H, Ar), 7.00 (d, *J* = 8.0 Hz, 2H, Ar), 7.11 (m, 1H, Ar), 7.25 (d, *J* = 8.0 Hz, 2H, Ar), 8.10 (s, 2H, NH₂), 8.87 (s, 1H, NH). ¹³C NMR (DMSO-*d*₆) δ 45.3 (2C), 49.4 (2C), 109.4 (d, ²*J*_{CF} = 13.6 Hz), 115.8 (d, ³*J*_{CF} = 7.1 Hz), 117.2 (d, ⁴*J*_{CF} = 3.6 Hz), 121.3 (2C), 125.0 (d, ³*J*_{CF} = 8.6 Hz), 127.6, 130.8 (2C), 142.8 (d, ³*J*_{CF} = 9.5 Hz), 145.8, 153.9 (d, ¹*J*_{CF} = 244.5 Hz), 163.0. IR (Nujol) 3431, 3165, 1645, 1627, 1597 cm⁻¹. *m/z* 429 (M + H)⁺. Anal. Calcd. for C₁₇H₁₈ClFN₄O₄S (428.87) C, 47.61; H, 4.23; N, 13.06. Found C, 47.66; H, 4.21; N, 13.10.

4.2.4.15. 4-(4-(2,3-Dimethylphenyl)piperazine-1-carboxamido)-3-fluorophenyl sulfamate (27)

Following the general procedure, the title compound was prepared starting from 2,3-dimethylphenylpiperazine. Yield 58%. M.p. 87-88°C. ¹H NMR (DMSO-*d*₆) δ 2.21 (s, 3H, CH₃), 2.23 (s, 3H, CH₃), 2.70 (s, 2H, CH₂), 2.87 (s, 2H, CH₂), 3.57 (s, 4H, CH₂), 6.57 (m, 2H, Ar), 6.91 (m, 3H, Ar), 7.11 (m, 1H, Ar), 8.07 (s, 2H, NH₂), 9.04 (s, 1H, NH). ¹³C NMR (DMSO-*d*₆) δ 16.8, 23.4, 44.2 (2C), 53.8 (2C), 109.6 (d, ²*J*_{CF} = 15.2 Hz), 112.1, 115.7 (d, ³*J*_{CF} = 8.1 Hz), 117.0 (d, ⁴*J*_{CF} = 3.5 Hz), 121.2, 122.1, 124.9 (d, ³*J*_{CF} = 8.4 Hz), 129.3, 140.2, 142.7 (d, ³*J*_{CF} = 9.0 Hz), 149.4, 154.3 (d, ¹*J*_{CF} = 243.6 Hz), 159.9. IR (Nujol) 3280, 1625, 1590 cm⁻¹. *m/z* 423 (M + H)⁺. Anal. Calcd. for C₁₉H₂₃FN₄O₄S (422.47) C, 54.02; H, 5.49; N, 13.26. Found C, 54.08; H, 5.47; N, 13.22.

4.2.4.16. 3-Fluoro-4-(4-octylpiperazine-1-carboxamido)phenyl sulfamate (28)

Following the general procedure, the title compound was prepared starting from *n*-octylpiperazine. Yield 11%. M.p. 78-79°C. ¹H NMR (DMSO-*d*₆) δ 0.87 (m, 3H, CH₃), 1.28 (m, 14H, CH₂), 2.45 (s, 4H, CH₂), 3.38 (s, 4H, CH₂), 7.22 (d, *J* = 7.0 Hz, 1H, Ar), 7.51 (s, 1H, Ar), 7.59 (d, *J* = 7.5 Hz, 1H, Ar), 7.73 (s, 2H, NH₂), 8.51 (s, 1H, NH). ¹³C NMR (DMSO-*d*₆) δ 17.1, 25.1, 28.7, 29.9, 31.8, 34.0 (2C), 46.8 (2C), 55.5 (2C), 60.7, 109.2 (d, ²*J*_{CF} = 12.8 Hz), 116.0 (d, ³*J*_{CF} = 8.4 Hz), 117.3 (d, ⁴*J*_{CF} = 3.6 Hz), 125.0 (d, ³*J*_{CF} = 8.6 Hz), 142.4 (d, ³*J*_{CF} = 8.4 Hz), 155.0 (d, ¹*J*_{CF} = 247.0 Hz), 161.2. IR (Nujol) 3430, 1644, 1596 cm⁻¹. *m/z* 431 (M + H)⁺. Anal. Calcd. for C₁₉H₃₁FN₄O₄S (430.54) C, 53.00; H, 7.26; N 13.01. Found C, 52.94; H, 7.29; N 13.05.

4.2.4.17. 4-(4-Decylpiperazine-1-carboxamido)-3-fluorophenyl sulfamate (29)

Following the general procedure, the title compound was prepared starting from *n*-decylpiperazine. Yield 12%. M.p. 81-82°C. ¹H NMR (DMSO-*d*₆) δ 0.92 (m, 3H, CH₃), 1.95 (m, 18H, CH₂), 2.17 (s, 4H, CH₂), 3.39 (s, 4H, CH₂), 7.15 (m, 1H, Ar), 7.44 (m, 1H, Ar), 7.77 (m, 1H, Ar), 7.80 (s, 2H, NH₂), 8.49 (s, 1H, NH). ¹³C NMR (DMSO-

δ 16.8, 25.2, 31.7 (2C), 31.9 (2C), 32.0, 33.1 (2C), 53.1 (2C), 57.6 (2C), 60.2, 109.3 (d, $^2J_{CF}$ = 12.7 Hz), 115.9 (d, $^3J_{CF}$ = 8.5 Hz), 117.5 (d, $^4J_{CF}$ = 3.5 Hz), 124.8 (d, $^3J_{CF}$ = 8.7 Hz), 142.2 (d, $^3J_{CF}$ = 8.5 Hz), 155.6 (d, $^1J_{CF}$ = 242.3 Hz), 159.1 IR (Nujol) 3346, 1644, 1614 cm^{-1} . m/z 459 (M + H)⁺. Anal. Calcd. for $\text{C}_{21}\text{H}_{35}\text{FN}_4\text{O}_4\text{S}$ (458.59) C, 55.00; H, 7.69; N 12.22. Found C, 55.06; H, 7.66; N, 12.26.

4.2.4.18. 3-Chloro-4-(4-octylpiperazine-1-carboxamido)phenyl sulfamate (**30**)

Following the general procedure, the title compound was prepared starting from *n*-octylpiperazine. Yield 38%. M.p. 106-107°C. ^1H NMR (DMSO- d_6) δ 0.93 (m, 3H, CH_3), 1.04 (m, 14H, CH_2), 2.18 (s, 4H, CH_2), 3.65 (s, 4H, CH_2), 7.24 (m, 1H, Ar), 7.60 (m, 2H, Ar), 7.90 (s, 2H, NH_2), 8.78 (s, 1H, NH). ^{13}C NMR (DMSO- d_6) δ 17.0, 25.2, 29.7, 31.8, 31.9, 34.4 (2C), 45.9 (2C), 55.2 (2C), 60.3, 119.3, 121.9, 123.1, 124.6, 135.8, 151.2, 157.9. IR (Nujol) 3324, 1636, 1603 cm^{-1} . m/z 447 (M + H)⁺. Anal. Calcd. for $\text{C}_{19}\text{H}_{31}\text{ClN}_4\text{O}_4\text{S}$ (446.99) C, 51.05; H, 6.99; N, 12.53. Found C, 51.11; H, 6.96; N, 12.57.

4.2.4.19. 3-Chloro-4-(4-decylpiperazine-1-carboxamido)phenyl sulfamate (**31**)

Following the general procedure, the title compound was prepared starting from *n*-decylpiperazine. Yield 35%. M.p. 57-58°C. ^1H NMR (DMSO- d_6) δ 0.95 (m, 3H, CH_3), 1.95 (m, 16H, CH_2), 2.11 (s, 2H, CH_2), 3.46 (s, 4H, CH_2), 3.88 (s, 2H, CH_2), 4.10 (s, 2H, CH_2), 7.26 (m, 1H, Ar), 7.40 (m, 1H, Ar), 7.70 (m, 1H, Ar), 7.89 (s, 2H, NH_2), 8.88 (s, 1H, NH). ^{13}C NMR (DMSO- d_6) δ 16.8, 25.2, 31.7 (2C), 31.9 (2C), 32.0, 33.1 (2C), 53.1 (2C), 57.6 (2C), 60.2, 119.7, 120.9, 122.2, 124.2, 131.6, 155.4, 157.0. IR (Nujol) 3307, 1639, 1608 cm^{-1} . m/z 476 (M + H)⁺. Anal. Calcd. for $\text{C}_{21}\text{H}_{35}\text{ClN}_4\text{O}_4\text{S}$ (475.04) C, 53.09; H, 7.43; N, 11.79. Found C, 53.14; H, 7.45; N, 11.75.

4.2.5. (E)-3-(Dimethylamino)-1-(3,4-dimethoxyphenyl)prop-2-en-1-one (**33f**)

A mixture of 3,4-dimethoxyacetophenone (0.9 g, 5 mmol) and DMF-DMA (1.79 g, 15 mmol) in anhydrous toluene (10 mL) was refluxed for 1 h, then was allowed to reach the room temperature and stirred for additional 24 h. The mixture was carefully concentrated in vacuum to the title compound in 77% yield. M.p. 113-114°C (n-hexane). ^1H NMR (DMSO- d_6) δ 2.91 (s, 3H, CH_3), 3.12 (s, 3H, CH_3), 3.81 (s, 6H, OCH_3), 5.81 (d, J = 12.0 Hz, 1H, CH), 6.97 (d, J = 8.0 Hz, 1H, Ar), 7.45 (s, 1H, Ar), 7.53 (d, J = 8.5 Hz, 1H, Ar), 7.65 (d, J = 12.0 Hz, 1H, CH). IR (Nujol) 3583, 1636 cm^{-1} . m/z 254 (M + H)⁺. Anal. Calcd. for $\text{C}_{13}\text{H}_{17}\text{NO}_3$ (253.28) C, 66.36; H, 7.28; N, 5.95. Found C, 66.27; H, 7.31; N, 5.93.

4.2.6. 4-(3,4-Dimethoxyphenyl)-2-(piperazin-1-yl)pyrimidine (**34f**)

A solution of (E)-3-(dimethylamino)-1-(3,4-dimethoxyphenyl)prop-2-en-1-one (0.51 g, 2 mmol), 4-(*tert*-butoxycarbonyl)piperazine-1-carboxamide (1.02 g, 2.2 mmol) and sodium methylate 30% MeOH solution (0.8 mL, 4 mmol) in anhydrous EtOH (5 mL) was refluxed 8 h. After cooling to room temperature the solvent was removed under reduced pressure. The residue was treated with ethyl acetate (20 mL) and washed with water (3 x 10 mL) and brine (10 mL). After drying over sodium sulphate the solvent was removed under reduced pressure. Then the residue was solubilised in anhydrous dichloromethane (10 mL) and trifluoroacetic acid (5 mL) was added. The mixture was stirred at room temperature overnight and after evaporation of the solvent, the residue was treated with a diethyl ether (20 mL) to obtain a solid that was filtered off and dried.

The formed solid was used in the next step without further purification. Yield 48%. M.p. >240°C. ¹H NMR (DMSO-d₆) δ 1.91 (s, 1H, NH), 2.79 (s, 4H, CH₂), 3.33 (s, 4H, CH₂), 4.31 (s, 6H, OCH₃), 6.97 (d, J = 7.0 Hz, 1H, Ar), 7.25 (s, 1H, Ar), 7.54 (d, J = 7.5 Hz, 1H, Ar), 7.85 (m, 2H, Ar). IR (Nujol) 3583, 1636 cm⁻¹. m/z 301 (M + H)⁺. Anal. Calcd. for C₁₆H₂₀N₄O₂ (300.36) C, 63.98; H, 6.71; N, 18.65. Found C, 63.87; H, 6.74; N, 18.70.

4.2.7. General procedure for the synthesis of 4-(4-(4-aryl)pyrimidin-2-yl)piperazinocarbonyl)aminophenyl sulfamates (**35-42**)

A mixture of 4-(phenoxy carbonyl)aminophenylsulfamate (0.31 g, 1 mmol) and pyrimidines **34a-h** (1 mmol), in anhydrous DMSO (3 mL) was stirred at room temperature for 24 h. Then, water (10 mL) was added and the mixture was stirred at room temperature until a solid is formed. The formed solid was filtered off, washed with water, air dried and recrystallized from EtOH to give ureas **35-42**.

4.2.7.1. 4-(4-(4-(3,4-Dimethoxyphenyl)pyrimidin-2-yl)piperazine-1-carboxamido)phenyl sulfamate (**40**)

Following the general procedure, the title compound was obtained in 27% yield. Oil. ¹H NMR (DMSO-d₆) δ 3.56 (s, 4H, CH₂), 3.83 (s, 4H, CH₂), 4.42 (s, 6H, CH₂), 7.07 (m, 2H, Ar), 7.19 (s, 1H, Ar), 7.45 (d, J = 7.5 Hz, 1H, Ar), 7.56 (d, J = 8.0 Hz, 2H, Ar), 7.77 (d, J = 7.0 Hz, 1H, Ar), 7.84 (s, 1H, NH), 8.33 (s, 2H, NH₂), 8.61 (d, J = 8.5 Hz, 2H, Ar). ¹³C NMR (DMSO-d₆) δ 51.1 (2C), 52.0 (2C), 57.2 (2C), 105.3, 108.6, 110.8, 121.3 (2C), 122.0, 123.3 (2C), 130.3, 133.6, 148.1, 150.3 (2C), 154.2, 155.5, 163.5, 166.7. IR (Nujol) 3328, 1634, 1516 cm⁻¹. m/z 515 (M + H)⁺. Anal. Calcd. for C₂₃H₂₆N₆O₆S (514.55) C, 53.69; H, 5.09; N, 16.33. Found C, 53.62; H, 5.11; N, 16.37.

4.3. STS assay

STS inhibitory assays were performed as described previously [19]. Briefly, the ability of a compound to inhibit STS activity was determined using the lysate of JEG-3, a human placenta choriocarcinoma cell line known to have high STS activity. To determine STS inhibition, activity was measured in the absence and presence of the inhibitor (0.001–10 μM) using [³H]E₁S (4 × 10⁵ dpm, Perkin Elmer) adjusted to 20 μM with unlabelled E₁S substrate. After incubation of the substrate-inhibitor with JEG-3 lysate (125 μg of protein/mL) for 1 h, the product formed estrone (E₁) was separated from the mixture by extraction with toluene (4 mL). [4-¹⁴C]E₁ (American Radiolabelled Chemicals) was also used throughout the assay to monitor procedural losses.

To ascertain whether compounds were able to pass through the cell lipid bilayer, intact monolayers of JEG-3 cells were incubated for 20 h at 37 °C with [³H]E₁S (5 pmol, 7 × 10⁵ dpm, 60 Ci/mmol) in serum-free Eagle's Minimal Essential Medium (1.0 mL) with or without inhibitors (10 μM). After incubation, medium (0.5 mL) was removed and product E₁ separated from E₁S by solvent partition using toluene (4 mL). [¹⁴C] Estrone (7 × 10³ dpm, 52 mCi/mmol) was used to correct for procedural losses. An organic phase aliquot was added to scintillation fluid and the ³H and ¹⁴C content measured by scintillation spectrometry. The mass of E₁S hydrolyzed was calculated from the ³H counts detected (corrected for the volume of medium and organic solvent used and for recovery of ¹⁴C counts) and the specific activity of the substrate.

Acknowledgment

This work was supported partially by the University of Cagliari FIR funds to GB and VO.

References

- [1] T. Saha, S. Makar, R. Swetha, G. Gutti, S. K. Singh, Estrogen signaling: An emanating therapeutic target for breast cancer treatment, *Eur. J. Med. Chem.* 177 (2019) 116-143.
- [2] S. Stanway, A. Purohit, L. W. L. Woo, S. Sufi, D. Vigushin, R. Ward, R. Wilson, F. Z. Stanczyk, N. Dobbs, E. Kulinskaya, M. Elliott, B. V. L. Potter, M. J. Reed, R. C. Coombes Phase I study of STX64 (667 Coumate) in breast cancer patients: the first study of a steroid sulphatase inhibitor, *Clin. Cancer Res.* 12 (2006) 1585-1592.
- [3] M.J. Reed, A. Purohit, L.W.L. Woo, S.P. Newman, B.V.L. Potter, Steroid sulfatase: molecular biology, regulation and inhibition, *Endocr. Rev.* 26 (2005) 171-202.
- [4] P.A. Foster, S.P. Newman, S.K. Chander, C. Stengel, R. Jhalli, L. W. L. Woo, B. V. L. Potter, M.J Reed, A. Purohit, A Second-Generation Steroid Sulfatase Inhibitor, for Hormone-Dependent Breast Cancer Therapy, *Clin. Cancer Res.* 12 (2006) 5543-5549.
- [5] R. Shah, J. Singh, D. Singh, A. S. Jaggi, N. Singh, Sulfatase inhibitors for recidivist breast cancer treatment: A chemical review, *Eur. J. Med. Chem.* 114 (2016) 170-177.
- [6] J.W. Mueller, L.C. Gilligan, J. Idkowiak, W. Arlt, P.A. Foster, The Regulation of Steroid Action by Sulfation and Desulfation, *Endocr. Rev.* 36 (2015) 526-563.
- [7] N. M. Howarth, A. Purohit, M, J, Reed, B. V. L. Potter, Estrone sulfamates: potent inhibitors of estrone sulfatase with therapeutic potential *J. Med. Chem.* 37 (1994) 219-221.
- [8] A. Purohit, G. J. Williams, N. M. Howarth, B. V. L. Potter, M. J. Reed, Inactivation of sulfatase by an active site-directed inhibitor, estrone-3-*O*-sulfamate, *Biochemistry* 34 (1995) 11508-11514.
- [9] M. P. Thomas, B. V. L. Potter, Discovery and Development of the Aryl *O*-Sulfamate Pharmacophore for Oncology and Women's Health, *J. Med. Chem.* 58 (2015) 7634-7658.
- [10] B. V. L. Potter, Steroid Sulfatase Inhibition by Aryl Sulfamates: Clinical Progress, Mechanism, and Future Prospects, *J. Mol. Endocrinol.* 61 (2018) 233-252.
- [11] S. Colette, S. Defrère, J. C. Lousse , A. Van Langendonck, J. P. Gotteland, E. Loumaye, J. Donnez, Inhibition of steroid sulfatase decreases endometriosis in an *in vivo* murine model, *Hum. Reprod.* 26 (2011) 1362-1370.
- [12] O. Pohl, E. Bestel, J. P. Gotteland, Synergistic effects of E2MATE and norethindrone acetate on steroid sulfatase inhibition: a randomized phase I proof-of-principle clinical study in women of reproductive age, *Reprod. Sci.* 21 (2014) 1256-1265.

- [13] A. Purohit, L. Fusi, J. Brosens, D. Parish, M. S. Fernandes, L. W. L. Woo, B. V. L. Potter, M. J. Reed, Inhibition of steroid sulphotase activity in endometriotic implants by 667 COUMATE: a potential new therapy, *Hum. Reprod.* 23 (2008) 290-297.
- [14] D. Poirier, R. P. Boivin, 17 α -alkyl- or 17 α -substituted benzyl-17 β -estradiols: a new family of estrone-sulphotase inhibitors, *Bioorg. Med. Chem. Lett.* 8 (1998) 1891-1896.
- [15] L. C. Ciobanu, R. P. Boivin, V. Luu-The, F. Labrie, D. Poirier, Potent inhibition of steroid sulphotase activity by 3-*O*-sulfamate 17 α -benzyl (or 4'-tert-butylbenzyl) estro-1, 3, 5 (10)-trienes: combination of two substituents at positions C3 and C17 α of estradiol, *J. Med. Chem.* 42 (1999) 2280-2286.
- [16] L. W. L. Woo, N. M. Howarth, A. Purohit, H. A. M. Hejaz, M. J. Reed and B. V. L. Potter, Steroidal and non-steroidal sulfamates as potent inhibitors of steroid sulphotase, *J. Med. Chem.* 41 (1998) 1068-1083.
- [17] L. W. L. Woo, A. Purohit, B. Malini, M. J. Reed, B. V. L. Potter, Potent active site-directed inhibition of steroid sulphotase by tricyclic coumarin-based sulphonamates, *Chem. Biol.* 7 (2000) 773-791.
- [18] D. Ganeshapillai, L. W. L. Woo, M. P. Thomas, A. Purohit, B. V. L. Potter, C-3 and C-4 Substituted Bicyclic Coumarin Sulfamates are Potent Steroid Sulphotase Inhibitors, *ACS Omega* 3 (2018) 10748–10772.
- [19] A. Purohit, L. W. L. Woo, A. Singh, C. J. Winterborn, B. V. L. Potter, M. J. Reed, *In vivo* activity of 4-methylcoumarin-7-*O*-sulfamate, a nonsteroidal, nonestrogenic sulphotase inhibitor, *Cancer Res.* 56 (1996) 4950-4955.
- [20] C. Palmieri, R.C. Stein, X. Liu, E. Hudson, H. Nicholas, H. Sasano, F. Guestini, C. Holcombe, S. Barrett, L. Kenny, IRIS study: a phase II study of the steroid sulphotase inhibitor Irosustat when added to an aromatase inhibitor in ER-positive breast cancer patients, *Breast Cancer Res. Treat.* 165 (2017) 343-353.
- [21] C. Palmieri, R. Szydło, M. Miller, L. Barker, N.H. Patel, H. Sasano, T. Barwick, H. Tam, D. Hadjilinas, J. Lee, IPET study: an FLT-PET window study to assess the activity of the steroid sulphotase inhibitor irosustat in early breast cancer. *Breast Cancer Res. Treat.* 166 (2017) 527-539.
- [22] P. Nussbaumer, D. Geyl, A. Horvath, P. Lehr, B. Wolff, A. Billich, Nortropinyl-arylsulfonylureas as novel, reversible inhibitors of human steroid sulphotase, *Bioorg. Med. Chem. Lett.* 13 (2003) 3673-3677.
- [23] P. Lehr, A. Billich, B. Wolff, P. Nussbaumer, *N*-Acyl arylsulfonamides as novel, reversible inhibitors of human steroid sulphotase, *Bioorg. Med. Chem. Lett.* 15 (2005) 1235-1238.
- [24] V. Ahmed, Y. Liu, S. D. Taylor, Multiple Pathways for the Irreversible Inhibition of Steroid Sulphotase with Quinone Methide-Generating Suicide Inhibitors. *Chem. Bio Chem.* 10 (2009) 1457–1461.
- [25] C. M. Phan, Y. Liu, B. M. Kim, Y. Mostafa, S. D. Taylor, Inhibition of steroid sulphotase with 4-substituted estrone and estradiol derivatives, *Bioorg. Med. Chem.* 19 (2011) 5999–6005.
- [26] S. Demkowicz, W. Kozak, M. Daśko, M. Maśtyk, B. Gielniewski, J. Rachon, Synthesis of bicoumarin thiophosphate derivatives as steroid sulphotase inhibitors, *Eur. J. Med. Chem.* 101 (2015) 358-366.
- [27] S. Demkowicz, W. Kozak, M. Dasko, A. Wołos, M. Maśtyk, K. Kubinski, A. Składanowski, M. Misiak, J. Rachon, Synthesis and steroid sulphotase inhibitory activities of *N*-alkanoyl tyramine phosphates and

thiophosphates, RSC Adv. 5 (2015) 32594-32603.

[28] L. W. L. Woo, C. Bubert, A. Purohit, B. V. L. Potter, Hybrid Dual Aromatase-Steroid Sulfatase Inhibitors with Exquisite Picomolar Inhibitory Activity, ACS Med. Chem. Lett. 2 (2011) 243–247.

[29] M. Daško, J. Rachon, M. Maslyk, K. Kubiński, S. Demkowicz Synthesis and biological evaluation of *N*-acylated tyramine sulfamates containing C-F bonds as steroid sulfatase inhibitors, Chem. Biol. Drug. Des. 90 (2017) 156-161.

[30] L. W. L. Woo et al B. V. L. Potter, Synthesis and structure-activity relationship studies of derivatives of the dual aromatase-sulfatase inhibitor 4-[[[4-cyanophenyl](4H-1,2,4-triazol-4-yl)amino]2methyl]phenyl sulfamate, Chem. Med. Chem. 8 (2013) 779-99.

[31] Li P.-K., S. Milano, L. Kluth, M.E. Rhodes, Synthesis and sulfatase inhibitory activities of non-steroidal estrone sulfatase inhibitors, J. Steroid Biochem. Mol. Biol. 59 (1996) 41-48.

[32] A. Kolli, G.H. Chu, M.E. Rhodes, K. Inoue, K.W. Selcer, P.-K. Li, Development of (*p*-*O*-sulfamoyl)-*N*-alkanoyl-phenylalkyl amines as non-steroidal estrone sulfatase inhibitors, J. Steroid Biochem. Mol. Biol. 68 (1999) 31-40.

[33] M. Okada, T. Nakagawa, S. Iwashita, S. Takegawa, T. Fujii, N. Koizumi, Development of novel steroid sulfatase inhibitors: Synthesis and biological evaluation of biphenyl-4-*O*-sulfamates, J. Steroid Biochem. Mol. Biol. 87 (2003) 141-148.

[34] M. I. El-Gamal, M. H. Semreen, P. A. Foster, B. V. L. Potter, Design, synthesis, and biological evaluation of new arylamide derivatives possessing sulfonate or sulfamate moieties as steroid sulfatase enzyme inhibitors, Bioorg. Med. Chem. 24 (2016) 2762-2767.

[35] C. Laurence, K.A. Brameld, J. Graton, J.Y. Le Questel, E. Renault, The pKBHX Database: Toward a Better Understanding of Hydrogen-Bond Basicity for Medicinal Chemists, J. Med. Chem. 52 (2009) 4073-4086.

[36] B. Kuhn, J.E. Fuchs, M. Reutlinger, M. Stahl, N.R Taylor, Rationalizing Tight Ligand Binding through Cooperative Interaction Networks, J. Chem. Inf. Model. 51 (2011) 3180-3198.

[37] A. Todorovic, C. Haskell-Luevano, A review of melanocortin receptor small molecule ligands, Peptides, 26 (2005), 2026-2036.

[38] M. Okada, S. Iwashita, N. Koizumi, Efficient General Method for Sulfamoylation of a Hydroxyl Group, Tetrahedron Lett. 41 (2000) 7047-7051.

[39] C. H. Mack, H. H. McGregor, Jr., S. R. Hobart, Synthesis of some phenyl *N*-arylcarbamates. J. Chem. Eng. Data 14 (1969) 258-261.

[40] D. L. Coffen, M. P. Dillon, A. P. Ford, Z. Li, T. J. Williams, US Patent 2002, 6355641 B1.

[41] C. Congiu, V. Onnis, A. Deplano, G. Balboni, M. Ceruso, C.T. Supuran Synthesis and carbonic anhydrase I, II, IX and XII inhibitory activity of sulfamates incorporating piperazinyl-ureido moieties. Bioorg. Med. Chem. 23 (2015) 5619-5625.